Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine Acetate Cardiac Repolarization Study
NCT02283788Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2007
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eslicarbazepine acetate in epilepsy (4 arms), sponsored by BIAL. Primary endpoint: QT Interval Individually Corrected for Heart Rate at Day 5. Started Mar 2007; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02283788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283788.